An at-home EEG headset paired with cognitive tasks detected early speech and facial-expression changes in ALS patients over eight months—shifts that standard clinic-based testing missed. The platform demonstrated high usability and data quality among people with severe motor impairment, addressing a critical gap in how cognitive and behavioral decline are tracked in neurodegenerative disease.
Key Points
- Home-based biweekly testing detected cognitive changes clinic testing missed
- 82% of ALS patients rated platform easy to use despite motor impairment
- 92% data completeness with effect sizes comparable to research-grade assessments
Longevity Analysis
Neurodegeneration detection depends on signal interpretation, and current clinical scales were designed to capture motor decline only. Frequent, objective measurement at home—rather than episodic clinic visits—reveals subtle shifts in cognition and behavior before they become clinically obvious. This matters because early detection of cognitive change in ALS and FTD reshapes intervention timing and trial design, moving treatment windows earlier in disease progression when therapeutic intervention may have greater impact. The platform demonstrates that rigorous measurement doesn't require a clinic setting; patients tolerate frequent self-administered assessment when it's designed with usability in mind, creating a feedback loop between better data and better patient engagement.
Original published by Longevity.Technology, by Kyle Umipig.